課程資訊
課程名稱
 生物科技管理與產業分析
Management and Analysis in the Biotechnology Industry 
開課學期
 102-2 
授課對象
 生物資源暨農學院  生物科技研究所  
授課教師
 孫智麗 
課號
 Biot7013 
課程識別碼
 642 M0140 
班次
  
學分
 2 
全/半年
 半年 
必/選修
 選修 
上課時間
 星期五6,7(13:20~15:10) 
上課地點
 生技所415 
備註
 限碩士班以上
總人數上限：20人 
Ceiba 課程網頁
 http://ceiba.ntu.edu.tw/1022Biot7013_ 
課程簡介影片
 
核心能力關聯
 核心能力與課程規劃關聯圖
課程大綱
為確保您我的權利,請尊重智慧財產權及不得非法影印
課程概述

歡迎具生物科技相關背景、或對生技產業分析與科技管理及技術評價有興趣者選修。
上課方式在期中考前由教師上課講授內容，在期中考後由修課同學從本學期課表以下七個主題中就其中一個主題所列參考文獻中選擇至少一篇或兩篇papers做口頭報告/ powperpoint簡報（依選課學生分配口頭報告、每個人口頭報告時間不超過30分鐘）；學期末要將個人選擇主題進行中文重點摘譯彙整報告/word檔（含圖表約3,000-4,500字）。  

課程目標
 課程核心能力發展目標：
1. 創新思考及問題解決能力
2. 團隊溝通與合作與能力
3. 領導與跨領域整合能力
4. 國際觀
5. 終身自我學習
課程內容涵蓋以下主題：
1. Industry Analysis
2. Market Analysis
3. Financing
4. Business Development
5. R&D Management
6. Technology Licensing
7. Technology Valuation 
課程要求
 學期成績評量方式：期中課堂表現（口頭簡報、學習態度與成效等）占50%；期末報告（中文重點摘譯彙整報告）占50%。修課同學在學期末要從本學期課表以下七個主題中選擇其中一個主題的至少兩篇papers進行中文重點摘譯彙整報告/word檔（12號字、含圖表約3,000-4,500字、專有名詞/公司名/技術名/藥名/人名不要翻成中文、檔案不超過1M），於6月25日前Email給教師（Email: juliesun@ntu.edu.tw）。  
預期每週課後學習時數
  
Office Hours
 另約時間 備註： 台灣經濟研究院 生物科技產業研究中心、智慧財產評價服務中心TEL: 02-25865000 ext.539 
指定閱讀
 上課講義：
1. 台灣生技產業發展現況
2. 全球生技醫藥產業發展趨勢
3. 前瞻農業生技發展未來趨勢
4. 生技產業分析-廠商與消費者調查
5. 生技產業分析-價值鏈/供應鏈、個案研究
6. 生物科技管理-技術評價原理與方法
7. 生物科技管理-技術評價案例分析 
參考書目
 1. Lessons from 60 years of pharmaceutical innovation, Nature Reviews Drug Discovery 8: p959, 2009.
2. The importance of new companies for drug discovery: origins of a decade of new drugs, Nature Reviews Drug Discovery 9: p867, 2010.
3. Strategic groups in the biopharmaceutical industry: implications for performance, Drug Discovery Today 14: p726, 2009.
4. Value networks identify innovation in 21st century pharmaceutical research, Drug Discovery Today 14: p68, 2009.
5. How many patents does a biopharmaceutical company need? Nature Biotechnology 26: p763, 2008.
6. What’s fueling the biotech engine 2012-2013, Nature Biotechnology 32: p32, 2014.
7. A decade of change, Nature Reviews Drug Discovery 11: p17, 2012.
8. 2013 FDA drug approvals, Nature Reviews Drug Discovery 13: p85, 2014.
9. Medicare formulary coverage for top – selling biologics, Nature Biotechnology 27: p1082, 2009.
10. The view beyond venture capital, Nature Biotechnology 32: p15, 2014.
11. Biotech's wellspring-the health of the private sector in 2012, Nature Biotechnology 31: p396, 2013.
12. Portfolio analysis and R&D decision making, Nature Reviews Drug Discovery 8: p189, 2009.
13. Pharmaceutical R&D: the road to positive returns, Nature Reviews Drug Discovery 8: p609, 2009.
14. The ‘big pharma’ dilemma: develop new drugs or promote existing ones? Nature Reviews Drug Discovery 8: p533, 2009.
15. Does R&D pay? Drug Discovery Today 15:230, 2010.
16. Commercialization strategies of young biotechnology firms, Research Policy 37: p1765, 2008.
17. Biotech acquisitions by big pharma: why and what is next, Drug Discovery Today 14: p818, 2009.
18. Six secrets to success—how to build a sustainable biotech business, Nature Biotechnology 27: p595, 2009.
19. The seven deadly sins of business development, Nature Biotechnology 26: p375, 2008.
20. Making the leap into entrepreneurship, Nature Biotechnology 28: p11, 2010.
21. The case for entrepreneurship in R&D in the pharmaceutical industry, Nature Reviews Drug Discovery 9:p683, 2010.
22. How were new medicines discovered? Nature Reviews Drug Discovery 10, p507, 2011.
23. Assessing the translatability of drug projects: what needs to be scored to predict success? Nature Reviews Drug Discovery 8: p541, 2009.
24. Drug discovery: are productivity metrics inhibiting motivation and creativity? Drug Discovery Today 13: p997, 2008.
25. Managing freedom: Managing researchers as if they were warriors, Drug Discovery Today 13: p555, 2008.
26. Project management of life-science research projects: project characteristics, challenges and training needs, Drug Discovery Today 16: p93, 2011.
27. Leveraging your biotech intellectual property, Nature Biotechnology 26: p607, 2008.
28. The economics of licensing contracts, Nature Biotechnology 26: p855, 2008.
29. Licensing: pros and cons for biotech, Drug Discovery Today 14: p227, 2009.
30. Reaching across the table, Nature Biotechnology 30: p485, 2012.
31. Disclosing discoveries, Nature Biotechnology 28: p9, 2010.
32. Coming to terms: Before taking other people’s money to finance your venture, it pays to fully educate yourself, Nature Biotechnology 28: p120, 2010.
33. How to improve R&D productivity: the pharmaceutical industry’s grand challenge, Nature Reviews Drug Discovery 9: p203, 2010.
34. The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics 28: p469, 2007.
35. Putting a price on biotechnology, Nature Biotechnology 19: p5, 2001. 
評量方式
(僅供參考)
    
課程進度
週次
日期
單元主題
第1週
 2/21  台灣生技產業發展現況 
第3週
 3/07  全球生技醫藥產業發展趨勢 
第4週
 3/14  前瞻農業生技發展未來趨勢 
第5週
 3/21  生技產業分析-廠商與消費者調查 
第6週
 3/28  生技產業分析-價值鏈/供應鏈、個案研究 
第8週
 4/11  生物科技管理-技術評價原理與方法 
第9週
 4/18  生物科技管理-技術評價案例分析 
第10週
 4/25  Industry Analysis:
1. Lessons from 60 years of pharmaceutical innovation, Nature Reviews Drug Discovery 8: p959, 2009.
2. The importance of new companies for drug discovery: origins of a decade of new drugs, Nature Reviews Drug Discovery 9: p867, 2010.
3. Strategic groups in the biopharmaceutical industry: implications for performance, Drug Discovery Today 14: p726, 2009.
4. Value networks identify innovation in 21st century pharmaceutical research, Drug Discovery Today 14: p68, 2009.
5. How many patents does a biopharmaceutical company need? Nature Biotechnology 26: p763, 2008.  
第11週
 5/02  Market Analysis:
6. What’s fueling the biotech engine 2012-2013, Nature Biotechnology 32: p32, 2014.
7. A decade of change, Nature Reviews Drug Discovery 11: p17, 2012.
8. 2013 FDA drug approvals, Nature Reviews Drug Discovery 13: p85, 2014.
9. Medicare formulary coverage for top – selling biologics, Nature Biotechnology 27: p1082, 2009.  
第12週
 5/09  Financing:
10. The view beyond venture capital, Nature Biotechnology 32: p15, 2014.
11. Biotech's wellspring-the health of the private sector in 2012, Nature Biotechnology 31: p396, 2013.
12. Portfolio analysis and R&D decision making, Nature Reviews Drug Discovery 8: p189, 2009.
13. Pharmaceutical R&D: the road to positive returns, Nature Reviews Drug Discovery 8: p609, 2009.
14. The ‘big pharma’ dilemma: develop new drugs or promote existing ones? Nature Reviews Drug Discovery 8: p533, 2009.
15. Does R&D pay? Drug Discovery Today 15:230, 2010. 
第13週
 5/16  Business Development:
16. Commercialization strategies of young biotechnology firms, Research Policy 37: p1765, 2008.
17. Biotech acquisitions by big pharma: why and what is next, Drug Discovery Today 14: p818, 2009.
18. Six secrets to success—how to build a sustainable biotech business, Nature Biotechnology 27: p595, 2009.
19. The seven deadly sins of business development, Nature Biotechnology 26: p375, 2008.
20. Making the leap into entrepreneurship, Nature Biotechnology 28: p11, 2010.
21. The case for entrepreneurship in R&D in the pharmaceutical industry, Nature Reviews Drug Discovery 9:p683, 2010. 
第14週
 5/23  R&D Management:
22. How were new medicines discovered? Nature Reviews Drug Discovery 10, p507, 2011.
23. Assessing the translatability of drug projects: what needs to be scored to predict success? Nature Reviews Drug Discovery 8: p541, 2009.
24. Drug discovery: are productivity metrics inhibiting motivation and creativity? Drug Discovery Today 13: p997, 2008.
25. Managing freedom: Managing researchers as if they were warriors, Drug Discovery Today 13: p555, 2008.
26. Project management of life-science research projects: project characteristics, challenges and training needs, Drug Discovery Today 16: p93, 2011. 
第15週
 5/30  Technology Licensing:
27. Leveraging your biotech intellectual property, Nature Biotechnology 26: p607, 2008.
28. The economics of licensing contracts, Nature Biotechnology 26: p855, 2008.
29. Licensing: pros and cons for biotech, Drug Discovery Today 14: p227, 2009.
30. Reaching across the table, Nature Biotechnology 30: p485, 2012.
31. Disclosing discoveries, Nature Biotechnology 28: p9, 2010.
32. Coming to terms: Before taking other people’s money to finance your venture, it pays to fully educate yourself, Nature Biotechnology 28: p120, 2010.  
第16週
 6/06  Technology Valuation:
33. How to improve R&D productivity: the pharmaceutical industry’s grand challenge, Nature Reviews Drug Discovery 9: p203, 2010.
34. The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics 28: p469, 2007.
35. Putting a price on biotechnology, Nature Biotechnology 19: p5, 2001. 
第17週
 6/13  台灣生技產業政策與發展策略 
第18週
 6/25  期末報告